leisure time -WSS

leisure time

author：fashion 2025-09-30 16:29:33 - browse：6

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： U.K. Biobank has 500,000 peoples' genome sequences available

focus

WSS

Organ aging and disease risk measured by new blood test

U.K. Biobank has 500,000 peoples' genome sequences available

Despite FDA concern, risk that CAR

New Covid vaccine is recommended for everyone 6 months or older

What don’t we know about an Alzheimer’s drug side effect?

Flagship Pioneering launches a new biotech in two countries

knowledge

leisure time

leisure time

Heart attack and stroke risk calculators need revising

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Bright Health sells Medicare Advantage business to Molina

Rep. Raul Ruiz on the physician shortage and more

Supreme Court strikes down use of affirmative action

Fetal surgery at risk from Dobbs and new abortion restrictions

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

PEPFAR is under serious threat — and so is global health

After affirmative action ruling, medical educators look to 'holistic review'

PEPFAR is under serious threat — and so is global health

hotspot

WATCH: Why do bright lights make us see spots?

Despite FDA concern, risk that CAR

J&J to emphasize cancer drugs, stop much of its vaccine research

New weight loss drugs vying to be the next Wegovy or Mounjaro

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

BIO selects John Crowley as new CEO

focus

explore

explore

hotspot